https://www.selleckchem.com/pr....oducts/pacap-1-38.ht
001), treatment for COVID-19 (p=0.006), and incomplete COVID-19 recovery (p=0.0267) but not with age, sex, MS type, race, disease duration, EDSS, vitamin D use, or disease modifying therapy use. COVID-19 severity and lack of complete systemic recovery were associated with new or worsening neurologic symptoms in 36.9% of MSRD patients. COVID-19 severity and lack of complete systemic recovery were associated with new or worsening neurologic symptoms in 36.9% of MSRD patients. Oxytocin, cortisol, and testosterone are involved in the pro
Like
Comment
Share
